NORTH: This phase II trial is testing the effectiveness of a new oral drug (Pabinostat) in paediatric and adult patients who have an osteosarcoma, rhabdoid tumour and/or neuroblastoma that has gotten worse or not responded to prior treatmentA Phase II Study of Panobinostat in Paediatric, Adolescent and Young Adult Patients with Solid Tumours Including Osteosarcoma, Malignant Rhabdoid Tumour/Atypical Teratoid Rhabdoid Tumours and Neuroblastoma

Summary

Participants in this trial will be stratified according to their diagnosis; osteosarcoma, neuroblastoma and MRT/ATRT. Patients will be enrolled following the end of their conventional therapy, which may include chemotherapy and/or radiation treatment. Patients will have a three-week wash out period before commencing on the trial. Pabinostat will be administered as a continuous daily oral dose, and will follow a dose escalation scheme for each stratum, determined by biological effect of the drug. The final dose will be defined when significant biological effect is achieved with acceptable toxicity, and is maintained for a 4 week period.

Conditions

This trial is treating patients with Osteosarcoma, Malignant Rhabdoid Tumour/Atypical Teratoid Rhabdoid Tumours or Neuroblastoma.

More information